연구동향 분석

Robust home brew fragment sizing assay for detection of MET exon 14 skipping mutation in non–small cell lung cancer patients in resource constrained community hospitals

Anurag Mehta Shrinidhi Nathany Aanchal Chopra Sakshi Mattoo Dushyant Kumar Manoj Kumar Panigrahi 2021년

논문상세정보
인용/피인용
' Robust home brew fragment sizing assay for detection of MET exon 14 skipping mutation in non–small cell lung cancer patients in resource constrained community hospitals' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Electrophoresis
  • Fragment sizing assay
  • Home brew
  • MET exon 14 skipping
  • lung neoplasms
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
129 0

0.0%

' Robust home brew fragment sizing assay for detection of MET exon 14 skipping mutation in non–small cell lung cancer patients in resource constrained community hospitals' 의 참고문헌

  • The race to target MET exon 14 skipping alterations in non-small cell lung cancer : the why, the how, the who, the unknown, and the inevitable
  • OncoKB: a precision oncology knowledge base
  • Nonamplification genetic alterations of HER2 gene in non-small cell lung carcinoma
    Mehta A [2021]
  • Next generation sequencing technology : advances and applications
    Buermans HP [2014]
  • Molecular diagnostic assays and clinicopathologic implications of MET exon 14 skipping mutation in non-small-cell lung cancer
    Kim EK [2019]
  • MET exon 14 skipping mutations in non-small-cell lung cancer: an overview of biology, clinical outcomes, and testing considerations
    Socinski MA [2021]
  • MET exon 14 skipping in non-small cell lung cancer
    Heist RS [2016]
  • MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung
    Saffroy R [2017]
  • MET exon 14 juxtamembrane splicing mutations : clinical and therapeutical perspectives for cancer therapy
    Pilotto S [2017]
  • MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis
    Tong JH [2016]
  • GEOMETRY Mono-1: phase II, multicenter study of MET inhibitor capmatinib (INC280) in EGFR wt , MET-dysregulated advanced NSCLC
    Wolf J [2017]
  • Cost-efficient and easy to perform PCR-based assay to identify Met exon 14 skipping in formalin-fixed paraffin-embedded(FFPE)non-small cell lung cancer(NSCLC)samples
    O’Brien O [2019]
  • Comprehensive molecular profiling of lung adenocarcinoma
  • Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations
    Schrock AB [2016]
  • An overview of the c-MET signaling pathway
    Organ SL [2011]